,124 Hence, anti-inflammation/anti-fibrosis strategies for treating NASH are considered effective by manipulating the targets including C-C chemokine receptor type 2/5 (Ccr2/5), tumor necrosis factor (TNF-α), vascular adhesion protein 1 (Vap-1), galectin-3, and apoptosis signal-regulating kinase 1 (Ask1). The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatohepatitis.